Gemeinschaftsklinikum Mittelrhein

Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients (2025) Rautenberg C, Middeke JM, Röllig C, Stelljes M, Gaidzik V, Kriege O, Verbeek M, et al. Journal article Approaches to Invasive Fungal Diseases in Paediatric Cancer Centres: An Analysis of Current Practices and Challenges in Germany, Austria and Switzerland (2025) Seidel D, Pana ZD, Ebrahimi-Fakhari D, Butzer SK, Mehler K, Reinhold I, Simon A, et al. Journal article Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia (2025) Ruhnke L, Bill M, Zukunft S, Eckardt JN, Schäfer S, Stasik S, Hanoun M, et al. Journal article Single or Double Induction With 7 1 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia (2024) Röllig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Hänel M, et al. Journal article Corrigendum to “Dissecting the genetic heterogeneity of gastric cancer” (eBioMedicine (2023) 92, (S2352396423001810), (10.1016/j.ebiom.2023.104616)) (2023) Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, et al. Journal article, Erratum Dissecting the genetic heterogeneity of gastric cancer (2023) Hess T, Maj C, Gehlen J, Borisov O, Haas SL, Gockel I, Vieth M, et al. Journal article ETOPOSIDE FOR PRIMARY HLH - BETTER THAN ITS REPUTATION (2023) Lehmberg K, Ledig S, Wustrau K, Kontny U, Westphal S, Hundsdoerfer P, Jorch N, et al. Conference contribution Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience (2023) Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, et al. Journal article Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4 (2023) Kayser S, Martínez-Cuadrón D, Hanoun M, Stölzel F, Gil C, Reinhardt HC, Aguiar E, et al. Journal article Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial (2022) Roellig C, Steffen B, Schliemann C, Mikesch JH, Alakel N, Herbst R, Haenel M, et al. Conference contribution